Pfizer Shares Outstanding 2010-2024 | PFE

Pfizer shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Pfizer shares outstanding for the quarter ending March 31, 2024 were 5.697B, a 0.52% decline year-over-year.
  • Pfizer 2023 shares outstanding were 5.709B, a 0.42% decline from 2022.
  • Pfizer 2022 shares outstanding were 5.733B, a 0.44% increase from 2021.
  • Pfizer 2021 shares outstanding were 5.708B, a 1.35% increase from 2020.
Pfizer Annual Shares Outstanding
(Millions of Shares)
2023 5,709
2022 5,733
2021 5,708
2020 5,632
2019 5,675
2018 5,977
2017 6,058
2016 6,159
2015 6,257
2014 6,424
2013 6,895
2012 7,508
2011 7,870
2010 8,074
2009 7,045
Pfizer Quarterly Shares Outstanding
(Millions of Shares)
2024-03-31 5,697
2023-12-31 5,709
2023-09-30 5,646
2023-06-30 5,713
2023-03-31 5,727
2022-12-31 5,733
2022-09-30 5,718
2022-06-30 5,712
2022-03-31 5,758
2021-12-31 5,708
2021-09-30 5,725
2021-06-30 5,678
2021-03-31 5,662
2020-12-31 5,632
2020-09-30 5,633
2020-06-30 5,619
2020-03-31 5,613
2019-12-31 5,675
2019-09-30 5,649
2019-06-30 5,672
2019-03-31 5,750
2018-12-31 5,977
2018-09-30 5,986
2018-06-30 5,952
2018-03-31 6,057
2017-12-31 6,058
2017-09-30 6,041
2017-06-30 6,037
2017-03-31 6,092
2016-12-31 6,159
2016-09-30 6,150
2016-06-30 6,149
2016-03-31 6,225
2015-12-31 6,257
2015-09-30 6,243
2015-06-30 6,243
2015-03-31 6,292
2014-12-31 6,424
2014-09-30 6,403
2014-06-30 6,444
2014-03-31 6,476
2013-12-31 6,895
2013-09-30 6,656
2013-06-30 7,117
2013-03-31 7,269
2012-12-31 7,508
2012-09-30 7,508
2012-06-30 7,537
2012-03-31 7,598
2011-12-31 7,870
2011-09-30 7,810
2011-06-30 7,935
2011-03-31 8,035
2010-12-31 8,074
2010-09-30 8,057
2010-06-30 8,072
2010-03-31 8,101
2009-12-31 7,045
2009-09-30 6,762
2009-06-30 6,752
2009-03-31 6,753
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $162.291B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01